The FDA has defended its decision to issue a refusal-to-file (RTF) letter for Moderna's new mRNA-based influenza vaccine, claiming the company had not used an appropriate control group in its pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results